Press Releases PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
3.61 ^USD	+7.76%		+11.08%	-27.36%

Mar. 28	B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating	MT
Mar. 27	Empire Metals targets key milestones in Australia	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer	Apr. 24	AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer	Apr. 23	AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	Mar. 28	AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	Mar. 27	AQ
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results	Mar. 20	AQ
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®	Mar. 13	AQ
PDS Biotechnology : Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Form 8-K	Mar. 13	PU
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer	Jan. 22	AQ
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference	Jan. 16	AQ
PDS Biotechnology Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Dec. 05	AQ
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Dec. 04	AQ
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer	Nov. 28	AQ
PDS Biotechnology: Q3 Earnings Snapshot	Nov. 14	AQ
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 14	AQ
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naive Patients at 36 Months	Nov. 10	AQ
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months	Nov. 09	AQ
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results	Nov. 07	AQ
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO	23-10-23	AQ
PDS Biotech Announces Interim Safety and Immune Response Data from Phase Clinical trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	23-10-12	AQ
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	23-10-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Press Releases

Filters